Type 2 diabetes: Assessment of endothelial lesion and fibrinolytic system markers

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 5, 2007, Pages 395-399

  Soares, Anna Letícia ^a   De Oliveira Sousa, Marinez ^a   Dusse, Luci Maria ^a   Fernandes, Ana Paula Salles Moura ^a   Lasmar, Marcelo Carvalho ^a   Novelli, Bethânia Alves ^a   De Fátima Guerra Lages, Geralda ^a   Das Graças Carvalho, Maria ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

D dimer; Homocysteine; Plasminogen activator inhibitor 1; Type 2 diabetes; Von Willebrand factor

Indexed keywords

D DIMER; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD VESSEL INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; MICROALBUMINURIA; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 34250864373     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328133f70f     Document Type: Article

References (24)

1. Fuller JH, Stevens LK, Wang S-L. Risk factors for cardiovascular mortality and morbidity: The WHO multinational study of vascular disease in diabetes. Diabetologia 2001; 44:S54-S64.
2. DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997; 50:191-197.
3. Nazimek-Siewniak B, Moczulski D, Grzeszczak W. Risk of macrovascular and microvascular complications in type 2 diabetes results of longitudinal study design. J Diabetes Complications 2002; 16:271-276.
4. Dodson PM. Hypertension and diabetes. Curr Med Res Opin 2002; 18:48-57.
5. Yamada T, Sato A, Nishimori T, Mitsuhashi T, Terao A, Sagai H, et al. Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes. Diabetes Res Clin Pract 2000; 49:23-31.
6. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complication 2001; 15:44-54.
7. Van Hinsberg VWM. The endothelium: vascular control of hemostasis. Eur J Obstet Gynecol Reprod Biol 2001; 95:198-201.
8. Ouviña SM, Greca RD, Zanaro NL, Palmer L, Sassetti B. Endothelial dysfuncion, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res 2001; 102:107-114.
9. Glueck CJ, Shaw P, Lang JE, Tracy T, Sieve-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75:132-136.
10. Matsuo T, Kobayashi H, Kario K, Suzuki S. Fibrin D-dimer in thrombogenic disorders. Semin Thromb Hemost 2000; 26:101-107.
11. Handin RI, Lux SE, Stossel TP. Blood: principles of hematology.. Philadelphia, PA: J.B. Lippincott; 1995.
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
13. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: WHO Department of Noncommunicable Disease Surveillance; 1999.
14. Hirano T, Ookubo K, Kashiwazaki K, Tajima H, Yoshino G, Adachi M. Vascular endothelial markers, von Willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease. Clin Chim Acta 2000; 299:65-75.
15. Dufour R, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recomendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000; 46:2050-2068.
16. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Diabetic nephropathy. Diabetes Care 2003; 26:S94-S98.
17. Stehouwer CDA, Gall M, Twisk JWR, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: prospective, interrelated, and independently associated with risk of death. Diabetes 2002; 51:1157-1165.
18. Blann AD, Lip GY. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinolysis 1998; 9:297-306.
19. Födinger M, Mannhalter C, Wölfl G, Pabinger I, Müller E, Schmid R, et al. Mutation (677C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patientes. Kidney Int 1997; 52:517-523.
20. Mazza A, Giugliano D, Motti C, Cortese C, Andreotti F, Marra G, et al. Glycemia, MTHFR genotype and low homocysteine in uncomplicated type 2 diabetic patients. Atherosclerosis 2000; 149:223-224.
21. Sumida Y, Wada H, Fujii M, Mori Y, Nakasaki T, Shimura M, et al. Increased soluble fibrin monomer and soluble thrombomodulin levels in non-insulin-dependent diabetes mellitus. Blood Coagul Fibrinolysis 1997; 8:303-307.
22. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 1983; 32:680-684.
23. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factor and cardiovascular risk in non-insulin-dependent Diabetes mellitus. Ann Med 1996; 28:371-380.
24. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance: evidence for a common antecedent? Diabetes Care 1999; 22:C25-C30.